利好医疗健康跨境贸易金融合规

汇宇制药3产品拟中标集采

来源：36kr · 发布：2026-08-02

汇宇制药旗下3个药品拟中标第十二批全国药品集中采购，涉及产品包括注射用盐酸伊立替康、注射用阿霉素等，中标后有望扩大市场份额并降低患者用药成本。

Huyu Pharma's three drugs tentatively won the 12th national drug procurement, including irinotecan hydrochloride injection and doxorubicin injection, potentially expanding market share and reducing patient medication costs.

为何重要： 中标将提升公司市场竞争力，推动仿制药规模化生产，助力医保控费与药品可及性，对行业集采常态化具有示范意义。 Winning bids enhances competitiveness, promotes scale production of generics, supports medical insurance cost control and drug accessibility, setting a benchmark for ongoing national procurement.

原文来源：36kr ↗（版权归原作者/原机构所有）

Original source: 36kr ↗ (copyright belongs to the original author/organization)

本页内容由 AI 自动整理自公开来源，仅供信息参考，不构成法律意见。版权归原作者/原机构所有。

Content on this page is AI-curated from public sources for information only — not legal advice. Copyright belongs to the original authors/organizations.